FAQ

Galantamine

Known as: Galanthamine, Lycoremine, Galantamine [Chemical/Ingredient] 
A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1953-2018
05010019532017

Related topics

Related topics

27 relations

Broader (5)

AlkaloidsAminesCholinesterase InhibitorsNootropic Agents
(More)
Alzheimer's DiseaseHypersensitivityIn BloodKidney Failure
(More)

Narrower (8)

NivalineRazadyneapogalanthaminegalantamine hydrobromide
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Galantamine
Alzheimer's Disease
physiological aspects
agonists
Amines
Hypersensitivity

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Galantamine in frontotemporal dementia and primary progressive aphasia.
BACKGROUND/AIMS The treatment of frontotemporal dementia (FTD) has been mainly symptomatic. Small randomized or open-label case… (More)
Is this relevant?
2007
2007
Galantamine treatment of vascular dementia: a randomized trial.
BACKGROUND To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD). METHODS In this… (More)
Is this relevant?
2006
2006
Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
BACKGROUND Cognition in schizophrenia is impaired in a variety of cognitive domains. Galantamine, a cholinesterase inhibitor with… (More)
Is this relevant?
2006
2006
A prospective, open-label trial of galantamine in autistic disorder.
OBJECTIVE Post-mortem studies have reported abnormalities of the cholinergic system in autism. The purpose of this study was to… (More)
Is this relevant?
2004
2004
Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.
Galantamine is a plant alkaloid that is used in the treatment of Alzheimer's disease. We have studied the effects of galantamine… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
BACKGROUND Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
OBJECTIVE To investigate the efficacy and tolerability of galantamine, using a slow dose escalation schedule of up to 8 weeks, in… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
BACKGROUND Galantamine is a reversible, competitive cholinesterase inhibitor that also allosterically modulates nicotinic… (More)
Is this relevant?
2000
2000
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
OBJECTIVE To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease. DESIGN Randomised, double… (More)
Is this relevant?